Apply now: feature your voice in our cell & gene therapy series
Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community?
We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice!
In a recent study by Pray et al. (2025), researchers found that a protein called TBL1X is abundant in Mantle Cell Lymphoma (MCL) cells and plays a crucial role in cell survival. By targeting TBL1X with a small molecule called Tegavivint, they were able to induce significant cell death in MCL cell lines and primary patient samples. This treatment also reduced tumor growth and prolonged survival in a mouse model of MCL.
The study also revealed that TBL1X helps maintain the stability of another protein, RAD51, which is important for the DNA damage response. When TBL1X was inhibited, RAD51 levels dropped, leading to DNA damage and cell death. These findings suggest that targeting TBL1X could be a promising new strategy for treating MCL, and further research is underway to explore this therapeutic approach.
More Info 
Add to Calendar